Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bio-Path Holdings has concluded treatment of the second dosage cohort in the company's Phase I clinical trial of its lead product candidate, BP-100-1.01 (Liposomal Grb-2).
Subscribe to our email newsletter
Liposomal Grb-2 is indicated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).
The second cohort of the Phase I study dosed a total of six patients, of which three evaluable patients completed the 28-day treatment cycle and while the other three failed to complete a full 28-day cycle because of disease progression.
Patients received a dose of 10 mg/m2 twice a week for four weeks, and found that Liposomal Grb-2, at a dose of 10 mg/m2 is well tolerated.
Liposomal Grb-2 is delivered via intravenous injection utilizing Bio-Path’s drug delivery technology that distributes nucleic acid drugs systemically and safely throughout the human body.